Skip to content
Open access

Noninvasive imaging-based vascular score is associated with immunotherapy outcome in non-small cell lung cancer

Sep 2026 · Scientific Reports · 0 citations

TL;DR

The vascular risk score (VRS), a deep learning–based imaging metric that quantifies abnormalities in tumor vasculature on CT scans, is presented and enables noninvasive, objective quantification of tumor vascular abnormality and may serve as a prognostic imaging marker in NSCLC.

Abstract

Morphological abnormality in tumor vasculature, a recently recognized mechanism of resistance to immune checkpoint inhibitors (ICIs), remains difficult to quantify due to its heterogeneity. We present the vascular risk score (VRS), a deep learning–based imaging metric that quantifies abnormalities in tumor vasculature on CT scans. We trained a deep learning model to learn representations of vascular morphology. Abnormality was then quantified using Gaussian mixture modeling as the degree to which each patient’s tumor vasculature deviated from the learned distribution of normal morphology. We validated VRS in a cohort of 321 NSCLC patients treated with ICIs. Patients with low VRS showed significantly longer progression-free and overall survival, and lower VRS was observed in patients with disease control compared with progressive disease. Combining VRS with PD-L1 expression provided modest additional discrimination over either marker alone. VRS enables noninvasive, objective quantification of tumor vascular abnormality and may serve as a prognostic imaging marker in NSCLC.

Read PDF

Similar papers

Open access

Advanced computational approaches for predicting immunotherapy response in non-small cell lung cancer based on clinical and histopathological data

Lung cancer remains one of the leading causes of cancer-related mortality worldwide, with most patients diagnosed at advanced stages where curative treatment is rarely possible. In advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs) have significantly improved patient outcomes by enhancing...

A. D. Ramos-Guerra · 0 citations
Open access Sep 2026

Risk assessment of thyroid cancer recurrence based on quantitative multiphoton imaging

Findings demonstrate that the developed model effectively stratifies recurrence risk in thyroid cancer and may serve as an objective, quantitative tool to support individualized postoperative monitoring and prognostic assessment.

Qiu-Yan He, Zi-Lu Lin, Han Wu et al. · 0 citations
Review Open access Sep 2026

Radiomics and deep learning for immune checkpoint inhibitor outcomes: imaging-derived immune phenotyping and clinical translation across solid tumors

This narrative review critically synthesizes the evidence across solid tumors and compares handcrafted radiomics, classical machine learning, convolutional neural networks, transformer-based approaches, self-supervised learning, and emerging foundation models, and discusses explainable AI, longitudinal imaging, pseudop...

Hang-Yu Wu, Jing Chen · 0 citations
Open access

Tissue and imaging biomarkers in the treatment of NSCLC

Characteristics of the tumor immune microenvironment and PET imaging of PD-1/PD-L1 have potential as biomarkers for immunotherapy in NSCLC are demonstrated and larger studies are required to validate the predictive value of these approaches.

A. Niemeijer · 0 citations
Review Sep 2026

Ultrasound Molecular Imaging and Visualization of Immune Biomarkers: A New Paradigm for Tumor Immunotherapy Response Assessment.

Cancer immunotherapy has revolutionized the treatment landscape, yet its clinical efficacy is limited by modest objective response rates and the emergence of atypical response patterns such as pseudoprogression and hyperprogression. Conventional RECIST criteria relying on anatomical size changes and invasive tissue bio...

Qiao-Ling Zhang, Shu-Fen Xiao, Jing-Xin He et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.